Sartorius Stedim Biotech company profile
Company profile
Sartorius Stedim Biotech has 10,483 employees and is headquartered in Aubagne, France.
Based in Aubagne, France, Sartorius Stedim Biotech S.A. has existed since its incorporation in 1978. The company makes instruments and consumables for the biopharmaceutical industry worldwide, among them cell culture media, bioreactors, separation and purification products, storage and transport systems for biological materials, pipettes, sensors, water purification systems and weighing products. Its customers include drug and vaccine manufacturers, food and chemical producers, and research and development laboratories. A collaboration with Bio Usawa Biotechnology, Ltd. covers antibody development in Africa.
In the fiscal year ended December 2025, revenue totaled EUR 2,967.5 million, up 6.7% on the prior year, and net income reached EUR 265.6 million. The company employed 10,483 people at the end of the period and is a subsidiary of Sartorius AG.
Company facts
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- France
- Headquarters
- Zone Industrielle Les Paluds, 13781, Aubagne
- Employees
- 10,483
- Chief executive
- Rene Faber
- Founded
- 1978
- Fiscal year
- January - December
- Listing
- DIM · Euronext Paris
- Currency
- EUR
- ISIN
- FR0013154002
- Website
- sartorius.com
Sartorius Stedim Biotech and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Sartorius Stedim BiotechDIM | France | $23.87B | 10,483 | 19.2% | 67.0 |
| Straumann HoldingSTMN | Switzerland | $20.65B | 11,582 | 24.7% | 47.1 |
| SartoriusSRT | Germany | $17.15B | 14,273 | 17.8% | 72.2 |
| ColoplastCOLO.B | Denmark | $16.83B | 17,270 | 25.7% | 37.2 |
| AlconALC | Switzerland | $35.37B | 25,000 | 12.9% | 56.8 |
| Ypsomed HoldingYPSN | Switzerland | $6.76B | 2,025 | 36.2% | 34.3 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
